On the malignant potential of thiopurine therapy

Blood. 2009 Jun 11;113(24):6258; author reply 6258-9. doi: 10.1182/blood-2009-03-208413.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Administration, Oral
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Combined Modality Therapy
  • Cranial Irradiation
  • Humans
  • Hypoxanthine Phosphoribosyltransferase / genetics
  • Immunoenzyme Techniques
  • Karyotyping
  • Mercaptopurine / administration & dosage
  • Mercaptopurine / adverse effects
  • Methotrexate / administration & dosage
  • Methotrexate / adverse effects
  • Methyltransferases / metabolism
  • Mutation / drug effects
  • Neoplasms, Second Primary / chemically induced*
  • Neoplasms, Second Primary / diagnosis
  • Neoplasms, Second Primary / metabolism
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy
  • Prognosis
  • Remission Induction
  • Risk Factors
  • Stem Cell Transplantation
  • Survival Rate
  • Treatment Outcome

Substances

  • Mercaptopurine
  • Methyltransferases
  • thiopurine methyltransferase
  • Hypoxanthine Phosphoribosyltransferase
  • Methotrexate